Mazzotta Annamaria, Esposito Maria, Carboni Isabella, Schipani Caterina, Chimenti Sergio
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
J Dermatolog Treat. 2007;18(2):84-7. doi: 10.1080/09546630601123835.
To establish the efficacy of clobetasol propionate foam 0.05% in patients with plaque-type psoriasis and scalp psoriasis.
We conducted an open-label study on 24 patients. Twelve patients affected by plaque-type psoriasis (group 1) and 12 patients with scalp psoriasis (group 2) applied clobetasol propionate foam 0.05% twice daily for 4 weeks.
Clobetasol propionate foam 0.05% led to a reduction of the disease severity. After 2 weeks the PASI score decreased from 7.5 at baseline to 2.5 (range: 0.8-4.6, SD: 1.1) in group 1 and from 5.7 to 1.7 (range: 0.2-4.8, SD: 1.1) in group 2. At week 4, the mean PASI was 2 (range: 0.6-4, SD: 1) and 1.1 (range: 0.2-2.2, SD: 0.6) in groups 1 and 2, respectively. In particular, at week 2, 83.3% of patients with plaque psoriasis and 75% with scalp psoriasis achieved an improvement of the PASI score from baseline> or =50% (PASI-50). At week 4, 91.6% of patients from group 1 and 100% from group 2 achieved or maintained PASI-50, while 41.6% in group 1 and 58.3% in group 2 demonstrated a further improvement, reaching PASI-75.
The rapidity of effect and the good safety profile suggest a role for clobetasol propionate foam 0.05% in the management of both plaque-type and scalp psoriasis.
确定0.05%丙酸氯倍他索泡沫剂对斑块型银屑病和头皮银屑病患者的疗效。
我们对24例患者进行了一项开放标签研究。12例斑块型银屑病患者（第1组）和12例头皮银屑病患者（第2组）每天两次外用0.05%丙酸氯倍他索泡沫剂，持续4周。
0.05%丙酸氯倍他索泡沫剂使疾病严重程度降低。第2周后，第1组的银屑病面积和严重程度指数（PASI）评分从基线时的7.5降至2.5（范围：0.8 - 4.6，标准差：1.1），第2组从5.7降至1.7（范围：0.2 - 4.8，标准差：1.1）。在第4周时，第1组和第2组的平均PASI分别为2（范围：0.6 - 4，标准差：1）和1.1（范围：0.2 - 2.2，标准差：0.6）。特别是在第2周时，83.3%的斑块型银屑病患者和75%的头皮银屑病患者PASI评分从基线改善≥50%（PASI - 50）。在第4周时，第1组91.6%的患者和第2组100%的患者达到或维持PASI - 50，而第1组41.6%的患者和第2组58.3%的患者进一步改善，达到PASI - 75。
起效迅速且安全性良好表明0.05%丙酸氯倍他索泡沫剂在斑块型和头皮银屑病的治疗中具有一定作用。
